Icatibant Newbury

Icatibant, the active ingredient in Icatibant Newbury, is a Bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance and reliable logistics for global healthcare providers. The company adheres to stringent manufacturing standards and provides comprehensive support for product handling and distribution.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

- Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of acute swelling episodes. - Hereditary angioedema type I: reduces the severity and duration of attacks. - Hereditary angioedema type II: alleviates symptoms during acute episodes.

Icatibant may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or erythema: localized skin irritation. - Swelling at injection site: transient edema. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Airway angioedema: swelling that may compromise breathing. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures.

- Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: caution advised; limited information on excretion in milk. - Renal impairment: monitor patients; no specific dosage adjustment is established. - Concomitant ACE inhibitors or ARBs: increased risk of angioedema; use with caution. - Known hypersensitivity: avoid in patients with documented allergy to icatibant or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase the risk of angioedema. - Angiotensin receptor blockers (ARBs): potential additive effect on bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema. - Diuretics: can influence fluid balance and blood pressure. - Other bradykinin pathway modulators: may alter therapeutic response.